levofloxacin has been researched along with Body Weight in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, AJ; Li, J; Li, X; Li, ZH; Qin, HL; Song, L; Wang, SQ; Wu, LQ; Zhang, HJ; Zhang, ZH | 1 |
| Busse, D; Huisinga, W; Ilia, L; Kloft, C; Michelet, R; Schaeftlein, A; Solms, A; Zeitlinger, M | 1 |
| Ji, S; Sun, L; Wang, N; Yang, W; Zhang, Y; Zhao, X; Zhu, LQ | 1 |
| Aarnoutse, R; Dooley, KE; Ganiem, AR; Gupta, A; Hesseling, A; Hibma, JE; McIlleron, H; Ramachandran, G; Ruslami, R; Savic, RM; Swaminathan, S; Thakur, K; van Crevel, R | 1 |
| Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW | 1 |
| Colino, CI; Ferrer, A; Grau, S; Luque, S; Valle, M | 1 |
| Blumer, JL; Bocchini, JA; Bradley, JS; Chien, S; Kearns, GL; Maldonado, S; Natarajan, J; Noel, GJ; Wells, TG | 1 |
| Almeida, A; Almeida, S; Caparrós, N; Filipe, A; Tanguay, M; Wong, H | 1 |
| Homma, M; Ohkohchi, N; Watanabe, M; Yuzawa, K | 1 |
| Doyle, E; Edelstein, MA; Edelstein, PH; Shinzato, T | 1 |
| Fujikawa, K; Harada, S; Ohura, K; Sasaki, T; Takayama, S; Watanabe, T | 1 |
| Ashby, R; Fowler, JS; Furuhama, K; Kato, M; Takayama, S; Woolley, AP | 1 |
| Hattori, C; Itoh, S; Matsuura, Y; Shimada, H; Tada, S | 1 |
| Domon, S; Kajimura, T; Kudo, G; Nomura, M; Takayama, S; Tojo, H; Yamada, M | 1 |
| Akahane, K; Inage, F; Kato, M; Takayama, S; Yoshida, M | 1 |
3 trial(s) available for levofloxacin and Body Weight
| Article | Year |
|---|---|
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Topics: Adolescent; Aging; Anthrax; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Body Weight; Child; Child, Preschool; Chromatography, High Pressure Liquid; Double-Blind Method; Female; Humans; Infant; Inhalation Exposure; Injections, Intravenous; Kidney Function Tests; Levofloxacin; Male; Ofloxacin; Spores, Bacterial; Tablets | 2010 |
Levofloxacin pharmacokinetics in children.
Topics: Administration, Oral; Adolescent; Age Factors; Anti-Infective Agents; Area Under Curve; Biological Availability; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Humans; Infant; Infusions, Intravenous; Injections, Intravenous; Inpatients; Levofloxacin; Metabolic Clearance Rate; Ofloxacin | 2005 |
Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomised, 2 x 2 crossover trial in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Biological Availability; Body Weight; Chemistry, Pharmaceutical; Cross-Over Studies; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Reproducibility of Results; Sex Characteristics; Therapeutic Equivalency | 2005 |
12 other study(ies) available for levofloxacin and Body Weight
| Article | Year |
|---|---|
Syntheses and structure-activity relationships on antibacterial and anti-ulcerative colitis properties of quaternary 13-substituted palmatines and 8-oxo-13-substituted dihydropalmatines.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Berberine Alkaloids; Body Weight; Candida albicans; Colitis, Ulcerative; Colon; Escherichia coli; Levofloxacin; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Structure; Muscle Contraction; Staphylococcus aureus; Structure-Activity Relationship; Sulfasalazine; X-Box Binding Protein 1 | 2018 |
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Height; Body Weight; Environmental Exposure; Humans; Levofloxacin; Male; Microdialysis; Middle Aged; Models, Statistical; Soft Tissue Infections | 2021 |
Population pharmacokinetics of intravenous levofloxacin 500 mg/day dosage in infected patients.
Topics: Adult; Aged; Aged, 80 and over; Aging; Algorithms; Anti-Infective Agents; Asian People; Body Weight; Chromatography, High Pressure Liquid; Female; Humans; Injections, Intravenous; Kidney Function Tests; Levofloxacin; Liver Function Tests; Male; Middle Aged; Models, Statistical; Precision Medicine; Prospective Studies; Reproducibility of Results; Young Adult | 2014 |
Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Computer Simulation; Drug Dosage Calculations; Humans; Infant; Levofloxacin; Models, Biological; Mycobacterium tuberculosis; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Meningeal | 2015 |
Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient.
Topics: Anti-Bacterial Agents; Body Weight; Humans; Infusions, Intravenous; Levofloxacin; Middle Aged; Obesity, Morbid; Ofloxacin; Pneumococcal Infections | 2011 |
Establishment of an animal model with side effects induced by mycophenolate mofetil and pharmacohistological analysis of them.
Topics: Animals; Body Weight; Diarrhea; Energy Intake; Feeding Behavior; Immunosuppressive Agents; Levofloxacin; Male; Mice; Mice, Inbred BALB C; Models, Animal; Mycophenolic Acid; Ofloxacin; Weight Loss | 2006 |
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Azithromycin; Body Weight; Fluoroquinolones; Gemifloxacin; Guinea Pigs; Half-Life; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Lung; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Survival Rate | 2001 |
Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits.
Topics: Animals; Anti-Infective Agents; Body Weight; Female; Levofloxacin; Male; Ofloxacin; Pregnancy; Prenatal Exposure Delayed Effects; Rabbits; Rats; Rats, Inbred Strains; Reproduction; Sexual Behavior, Animal; Teratogens | 1992 |
Twenty-six-week oral toxicity of the new quinolone antibacterial agent levofloxacin in rats and cynomolgus monkeys.
Topics: Animals; Anti-Infective Agents; Blood Cell Count; Body Weight; Eating; Electrocardiography; Female; Levofloxacin; Macaca fascicularis; Male; Ofloxacin; Organ Size; Rats; Rats, Inbred Strains | 1992 |
Mutagenicity of the new quinolone antibacterial agent levofloxacin.
Topics: Animals; Anti-Infective Agents; Body Weight; Cell Line; Cell Survival; CHO Cells; Chromosome Aberrations; Cricetinae; DNA; Escherichia coli; Female; Levofloxacin; Male; Mice; Mice, Inbred Strains; Micronucleus Tests; Mutagens; Ofloxacin; Pregnancy; Rats; Rats, Inbred F344; Salmonella typhimurium; Sister Chromatid Exchange | 1992 |
Effect of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in rats.
Topics: Animals; Anti-Infective Agents; Body Weight; Carcinogens; Drinking; Eating; Levofloxacin; Male; Neoplasms, Experimental; Ofloxacin; Rats; Rats, Inbred F344 | 1992 |
Lack of nephrotoxic effects of the new quinolone antibacterial agent levofloxacin in rabbits.
Topics: Animals; Anti-Infective Agents; Blood Urea Nitrogen; Body Weight; Cephaloridine; Creatinine; Kidney Diseases; Levofloxacin; Male; Ofloxacin; Organ Size; Rabbits | 1992 |